Zolbetuximab with chemotherapy for advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new drug called zolbetuximab added to standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer. It may help slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery.
- Your tumor must have a certain marker called CLDN18.2 in at least 75% of cells, and must be HER2-negative.
- You have not had chemotherapy for advanced cancer before (you may have had it before surgery or as a preventive treatment).
- You are generally in good health (able to do light activity) and expected to live at least 12 weeks.
- You are not pregnant, breastfeeding, or planning to donate sperm or eggs during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well zolbetuximab works when combined with chemotherapy in people with advanced stomach or gastroesophageal junction cancer. It aims to help doctors understand the best ways to use this treatment in everyday practice.
This trial tests a new combination of drugs (zolbetuximab, pembrolizumab, and chemotherapy) for people with advanced stomach or gastroesophageal junction cancer. It may be an option if your tumor has certain proteins (CLDN18.2 and PD-L1) and you haven't had chemotherapy for advanced disease.
This early access program offers the investigational drug zolbetuximab for people with advanced stomach cancer that has a specific protein marker. The study aims to make this targeted treatment available before it is fully approved, potentially helping those who have limited options.
This trial tests a new drug called zolbetuximab combined with chemotherapy (docetaxel, oxaliplatin, S-1) before surgery for people with locally advanced stomach cancer that has a specific protein (CLDN18.2). The goal is to see if this combination shrinks tumors enough to improve surgery outcomes.
This trial tests a combination of three drugs (zolbetuximab, paclitaxel, and ramucirumab) for people with advanced stomach or esophagus cancer that has a specific protein called CLDN18.2. It may be an option if you've already had one standard treatment.
This study tests a new combination treatment for advanced stomach or gastro-esophageal cancer that has not responded to standard treatments. The trial aims to see if the drug combination is safe and effective, potentially offering a new option for people with this type of cancer.
Hear when a new Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.